Literature DB >> 25017477

Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data.

Donavan T Cheng1, Janice Cheng2, Talia N Mitchell2, Aijazuddin Syed2, Ahmet Zehir2, Nana Yaa T Mensah2, Alifya Oultache2, Khedoudja Nafa2, Ross L Levine3, Maria E Arcila2, Michael F Berger4, Cyrus V Hedvat2.   

Abstract

Amplicon-based methods for targeted resequencing of cancer genes have gained traction in the clinic as a strategy for molecular diagnostic testing. An 847-amplicon panel was designed with the RainDance DeepSeq system, covering most exons of 28 genes relevant to acute myeloid leukemia and myeloproliferative neoplasms. We developed a paired-sample analysis pipeline for variant calling and sought to assess its sensitivity and specificity relative to a set of samples with previously identified mutations. Thirty samples with known mutations in JAK2, NPM1, DNMT3A, MPL, IDH1, IDH2, CEBPA, and FLT3, were profiled and sequenced to high depth. Variant calling using an unmatched Hapmap DNA control removed a substantial number of artifactual calls regardless of algorithm used or variant class. The removed calls were nonunique, had lower variant frequencies, and tended to recur in multiple unrelated samples. Analysis of sample replicates revealed that reproducible calls had distinctly higher variant allele depths and frequencies compared to nonreproducible calls. On the basis of these differences, filters on variant frequency were chosen to select for reproducible calls. The analysis pipeline successfully retrieved the associated known variant in all tested samples and uncovered additional mutations in some samples corresponding to well-characterized hotspot mutations in acute myeloid leukemia. We have developed a paired-sample analysis pipeline capable of robust identification of mutations from microdroplet-PCR sequencing data with high sensitivity and specificity.
Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25017477      PMCID: PMC5707185          DOI: 10.1016/j.jmoldx.2014.05.006

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  36 in total

1.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.

Authors:  Daniel C Koboldt; Qunyuan Zhang; David E Larson; Dong Shen; Michael D McLellan; Ling Lin; Christopher A Miller; Elaine R Mardis; Li Ding; Richard K Wilson
Journal:  Genome Res       Date:  2012-02-02       Impact factor: 9.043

2.  VarScan: variant detection in massively parallel sequencing of individual and pooled samples.

Authors:  Daniel C Koboldt; Ken Chen; Todd Wylie; David E Larson; Michael D McLellan; Elaine R Mardis; George M Weinstock; Richard K Wilson; Li Ding
Journal:  Bioinformatics       Date:  2009-06-19       Impact factor: 6.937

Review 3.  Keeping up with the next generation: massively parallel sequencing in clinical diagnostics.

Authors:  John R ten Bosch; Wayne W Grody
Journal:  J Mol Diagn       Date:  2008-10-02       Impact factor: 5.568

4.  The Catalogue of Somatic Mutations in Cancer (COSMIC).

Authors:  S A Forbes; G Bhamra; S Bamford; E Dawson; C Kok; J Clements; A Menzies; J W Teague; P A Futreal; M R Stratton
Journal:  Curr Protoc Hum Genet       Date:  2008-04

Review 5.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

Authors:  Guido Marcucci; Torsten Haferlach; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

6.  Global mutational profiling of formalin-fixed human colon cancers from a pathology archive.

Authors:  Mark D Adams; Martina L Veigl; Zhenghe Wang; Neil Molyneux; Shuying Sun; Kishore Guda; Xiaoqing Yu; Sanford D Markowitz; Joseph Willis
Journal:  Mod Pathol       Date:  2012-08-10       Impact factor: 7.842

7.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Authors:  Animesh D Pardanani; Ross L Levine; Terra Lasho; Yana Pikman; Ruben A Mesa; Martha Wadleigh; David P Steensma; Michelle A Elliott; Alexandra P Wolanskyj; William J Hogan; Rebecca F McClure; Mark R Litzow; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

Review 8.  The evolving molecular genetic landscape in acute myeloid leukaemia.

Authors:  Mathijs A Sanders; Peter J M Valk
Journal:  Curr Opin Hematol       Date:  2013-03       Impact factor: 3.284

9.  IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2010-10       Impact factor: 11.047

10.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

View more
  17 in total

Review 1.  Molecular therapy for acute myeloid leukaemia.

Authors:  Catherine C Coombs; Martin S Tallman; Ross L Levine
Journal:  Nat Rev Clin Oncol       Date:  2015-12-01       Impact factor: 66.675

2.  PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Authors:  Wenbin Xiao; Maheetha Bharadwaj; Max Levine; Noushin Farnhoud; Friederike Pastore; Bartlomiej M Getta; Anne Hultquist; Christopher Famulare; Juan S Medina; Minal A Patel; Qi Gao; Natasha Lewis; Janine Pichardo; Jeeyeon Baik; Brian Shaffer; Sergio Giralt; Raajit Rampal; Sean Devlin; Robert Cimera; Yanming Zhang; Maria E Arcila; Elli Papaemmanuil; Ross L Levine; Mikhail Roshal
Journal:  Blood Adv       Date:  2018-12-11

3.  Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.

Authors:  Catherine C Coombs; David A Sallman; Sean M Devlin; Shweta Dixit; Abhinita Mohanty; Kristina Knapp; Najla H Al Ali; Jeffrey E Lancet; Alan F List; Rami S Komrokji; Eric Padron; Maria E Arcila; Virginia M Klimek; Marcel R M van den Brink; Martin S Tallman; Ross L Levine; Raajit K Rampal; Franck Rapaport
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

4.  Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms.

Authors:  Gabriela S Hobbs; Amritha Varshini Hanasoge Somasundara; Maria Kleppe; Rivka Litvin; Maria Arcila; Jihae Ahn; Anna Sophia McKenney; Kristina Knapp; Ryan Ptashkin; Howard Weinstein; Murk-Hein Heinemann; Jasmine Francis; Suzanne Chanel; Ellin Berman; Michael Mauro; Martin S Tallman; Mark L Heaney; Ross L Levine; Raajit K Rampal
Journal:  Haematologica       Date:  2017-10-19       Impact factor: 9.941

5.  Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.

Authors:  Bartlomiej M Getta; Mikhail Roshal; Junting Zheng; Jae H Park; Eytan M Stein; Ross Levine; Esperanza B Papadopoulos; Ann A Jakubowski; Nancy A Kernan; Peter Steinherz; Richard J O'Reilly; Miguel-Angel Perales; Sergio A Giralt; Martin S Tallman; Brian C Shaffer
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-08       Impact factor: 5.742

6.  Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.

Authors:  Michael V Ortiz; Rachel Kobos; Michael Walsh; Emily K Slotkin; Stephen Roberts; Michael F Berger; Meera Hameed; David Solit; Marc Ladanyi; Neerav Shukla; Alex Kentsis
Journal:  Pediatr Blood Cancer       Date:  2016-04-15       Impact factor: 3.167

Review 7.  Secondary mutations as mediators of resistance to targeted therapy in leukemia.

Authors:  Naval Daver; Jorge Cortes; Farhad Ravandi; Keyur P Patel; Jan A Burger; Marina Konopleva; Hagop Kantarjian
Journal:  Blood       Date:  2015-03-20       Impact factor: 22.113

Review 8.  The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice.

Authors:  Frank C Kuo; Brenton G Mar; R Coleman Lindsley; Neal I Lindeman
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

9.  Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.

Authors:  Michael J Kluk; R Coleman Lindsley; Jon C Aster; Neal I Lindeman; David Szeto; Dimity Hall; Frank C Kuo
Journal:  J Mol Diagn       Date:  2016-07       Impact factor: 5.568

10.  The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes.

Authors:  Olca Basturk; Marcus Tan; Umesh Bhanot; Peter Allen; Volkan Adsay; Sasinya N Scott; Ronak Shah; Michael F Berger; Gokce Askan; Esra Dikoglu; Vaidehi Jobanputra; Kazimierz O Wrzeszczynski; Carlie Sigel; Christine Iacobuzio-Donahue; David S Klimstra
Journal:  Mod Pathol       Date:  2016-06-10       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.